Clarithromycin Cuts Pneumonia Hospital Costs by Nearly Half in Landmark Trial

Community-acquired pneumonia remains one of the most stubborn drains on hospital budgets worldwide, and a new economic analysis from a rigorously controlled clinical trial suggests that a cheap, decades-old antibiotic may shrink that drain dramatically. In a prespecified within-trial cost analysis of the ACCESS study, published in BMC Infectious Diseases, researchers in Athens found that adding clarithromycin to standard pneumonia therapy reduced mean cumulative hospitalization costs by roughly 43 percent by day 90, a saving driven almost entirely by less time and expenditure in the intensive care unit.

The ACCESS trial was a phase 3, prospective, double-blind, randomized, placebo-controlled study conducted among 267 adults hospitalized with community-acquired pneumonia in Greece. Participants received standard-of-care antibiotics, typically a β-lactam, together with either adjunctive clarithromycin or an identical placebo. The design matters enormously for the new findings: because the cost analysis was performed within the same randomized framework as the clinical outcomes, the economic estimates inherit the protection against confounding that observational cost studies so often lack. Patients were not selected into cheaper or costlier treatment pathways by severity, comorbidity, or physician preference; the randomization did that work for the analysts.

To translate hospital resource use into euros, the team relied on the officially sanctioned Greek Diagnosis-Related Groups reimbursement tariffs, which assign fixed prices to ward days, intensive care unit days, and drug administration. Prospectively collected trial data on length of stay, ICU admission, and antibiotic duration were then mapped onto these tariffs, allowing the researchers to compute cumulative hospitalization expenditure through day 90 for every participant. Between-group differences in mean cumulative costs were estimated with bootstrap analysis, a resampling technique that generates 95 percent confidence intervals without assuming a particular parametric distribution of costs, which is crucial because healthcare cost data are notoriously skewed by a minority of very expensive patients.

The headline numbers are striking. By day 90, mean per-capita hospitalization costs stood at €1158.5 in the clarithromycin group versus €2029.9 in the placebo group, a mean difference of -€871.4 with a 95 percent confidence interval stretching from -€1661.2 to -€222.5. The confidence interval excludes zero, indicating that the cost advantage is unlikely to be a statistical fluke, though its width also signals genuine uncertainty about the exact magnitude of the saving. The clarithromycin group’s figure represents an approximately 43 percent reduction in mean cumulative costs, a proportion that would command attention in any health ministry’s spreadsheet.

Peeling the analysis open reveals where the money was actually saved. ICU-related expenditure, the single most expensive component of pneumonia care, averaged €3556.3 among clarithromycin recipients compared with €6653.0 among placebo recipients, a mean difference of -€3096.8 with a 95 percent confidence interval from -€6661.2 to -€192.7. In other words, the entire cost advantage of the macrolide can be attributed to keeping patients out of intensive care or shortening their stay there. Ward costs and drug costs contributed comparatively little, which is intuitive: the antibiotic itself is inexpensive, but a single day in an ICU can consume more resources than a week on a general medical ward.

The clinical data underlying these costs tell a coherent story. Median duration of antibiotic treatment was 9.5 days in the clarithromycin arm versus 14 days in the placebo arm, a difference that reached statistical significance at p = 0.049. Median time to hospital discharge alive was similarly 9 versus 14 days. Shorter antibiotic courses and earlier discharge are not merely accounting conveniences; they reflect faster clinical stabilization, and they carry secondary benefits in an era of mounting antimicrobial resistance, since fewer days of broad-spectrum therapy mean less selective pressure on hospital flora and a smaller reservoir of resistant organisms.

Why would a macrolide produce these effects? The ACCESS investigators have previously explored the immunomodulatory properties of clarithromycin, which extend well beyond its antibacterial action. Macrolides are known to dampen excessive inflammatory signaling, modulate cytokine release, and influence the complement cascade, the arm of innate immunity that the trial’s related subjects explicitly flag. In severe pneumonia, much of the tissue damage and organ dysfunction arises not from the bacteria themselves but from a dysregulated host response, and an agent that tempers that response while also covering atypical pathogens such as Mycoplasma pneumoniae and Chlamydophila pneumoniae could plausibly shorten the trajectory toward critical illness.

The authors are careful about the boundaries of their claims. The cost estimates are anchored to the current Greek reimbursement framework, and Diagnosis-Related Group tariffs differ substantially across countries, so the absolute euro figures will not transfer mechanically to, say, a German or American hospital system. The trial was conducted in a single national context, and the confidence intervals around the ICU cost difference, while excluding zero, are wide enough to accommodate considerable variation in the true saving. The team also emphasizes that a formal cost-effectiveness assessment, one that weighs costs against quality-adjusted life years or other outcome measures under the CHEERS 2022 reporting standards, is needed to develop this line of research into policy guidance.

Methodological transparency was a priority for the analysis. The study was registered in the European Clinical Trials Database as EudraCT 2020-004452-15 and at ClinicalTrials.gov as NCT04724044, and ethical approval came from the Greek National Ethics Committee and the National Organization for Medicines of Greece, with written informed consent obtained from all participants or their legally authorized representatives. The ACCESS trial was sponsored by the Hellenic Institute for the Study of Sepsis and funded by Abbott Products Operations, with the sponsor responsible for study design, conduct, analysis, and the decision to publish, while the funding body had no role in those activities. The cost analysis followed the CHEERS 2022 checklist for reporting health economic evaluations, and supplementary tables document the sanctioned hospitalization costs, drug acquisition prices, and cumulative expenditure by treatment group.

For clinicians and health economists, the findings land at a moment when pneumonia’s economic burden is under intensifying scrutiny. Combination therapy with a β-lactam and a macrolide is already widely recommended in guidelines for hospitalized community-acquired pneumonia, yet the cost consequences of the adjunctive macrolide component had received remarkably little rigorous investigation. This analysis supplies the missing economic dimension to a randomized evidence base, and it does so with a design that observational pharmacoeconomic studies cannot replicate. If the pattern holds in cost-effectiveness modeling and in other reimbursement environments, a cheap oral antibiotic that has been on pharmacy shelves for generations could emerge as one of the most economically rational interventions in modern pneumonia care, sparing patients intensive care and sparing health systems the expense that comes with it.

Subject of Research: Clarithromycin in community-acquired pneumonia: a within-trial cost analysis of the ACCESS randomised, double-blind, placebo-controlled study

Article Title: Clarithromycin in community-acquired pneumonia: a within-trial cost analysis of the ACCESS randomised, double-blind, placebo-controlled study

Article References: Rapti, V., Antonakos, N., Mesiri, P., Giamarellos-Bourboulis, E. J., & Poulakou, G. (2026). Clarithromycin in community-acquired pneumonia: a within-trial cost analysis of the ACCESS randomised, double-blind, placebo-controlled study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14635-2

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14635-2

Keywords: Clarithromycin, community-acquired, pneumonia, within-trial, cost, analysis, ACCESS, randomised, double-blind, placebo-controlled, scientific research